Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity

Neurourology and Urodynamics

Volumn 32, Issue 3, 2013, Pages 242-249

  Sussman, David ^a   Patel, Vaishali ^b   Del Popolo, Giulio ^c   Lam, Wayne ^b   Globe, Denise ^b   Pommerville, Peter ^d  

^a UMDNJ School of Osteopathic Medicine   (United States)

^b ALLERGAN INC   (United States)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d Can Med Clinical Research Inc   (Canada)

Author keywords

neurogenic detrusor overactivity; onabotulinumtoxinA; QoL; satisfaction; urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EMOTION; FEMALE; HUMAN; INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE; INTERMITTENT CATHETERIZATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROGENIC DETRUSOR OVERACTIVITY; OVERACTIVE BLADDER; OVERACTIVE BLADDER PATIENT SATISFACTION WITH TREATMENT QUESTIONNAIRE; PATIENT GLOBAL ASSESSMENT; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE;

ADULT; ANALYSIS OF VARIANCE; BOTULINUM TOXINS, TYPE A; BRAZIL; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; NORTH AMERICA; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; SOUTH AFRICA; TAIWAN; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE;

EID: 84875382681     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22293     Document Type: Article

References (25)

1. Foley SJ, McFarlane JP, Shah PJ,. Vesico-ureteric reflux in adult patients with spinal injury. Br J Urol 1997; 79: 888-91.
2. Giannantoni A, Mearini E, Del Zingaro M, et al. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: Clinical and urodynamic results. Eur Urol 2009; 55: 705-11.
3. Clanet MG, Brassat D,. The management of multiple sclerosis patients. Curr Opin Neurol 2000; 13: 263-70.
4. Hicken BL, Putzke JD, Richards JS,. Bladder management and quality of life after spinal cord injury. Am J Phys Med Rehabil 2001; 80: 916-22.
5. Westgren N, Levi R,. Quality of life and traumatic spinal cord injury. Arch Phys Med Rehabil 1998; 79: 1433-39.
6. Abrams P, Andersson KE,. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987-6.
7. Cameron AP,. Pharmacologic therapy for the neurogenic bladder. Urol Clin North Am 2010; 37: 495-506.
8. Athanasopoulos A, Cruz F,. The medical treatment of overactive bladder, including current and future treatments. Expert Opin Pharmacother 2011; 12: 1041-55.
9. Jundt K, Schreyer K, Friese K, et al. Anticholinergic therapy: Do the patients take the pills prescribed ? Arch Gynecol Obstet 2010; 284: 663-6.
10. Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010; 105: 1276-82.
11. Schurch B, Denys P, Barron RB, et al. Botulinum toxin A (BoNTA) treatment in patients with neurogenic urinary incontinence shows significant improvements on the incontinence quality of life questionnaire. Eur J Neurol 2005; 12: 254.
12. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomized, double-blind, placebo-controlled trial. Eur Urol 2011; 60: 742-50.
13. Schurch B, Denys P, Kozma CM, et al. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil 2007; 88: 646-52.
14. Barron R,. Exploratory and confirmatory factor analysis of an overactive bladder-patient satisfaction with treatment questionnaire. Qual Life Res 2005; 14: 2095.
15. Barron R, Sissins P,. Development of a patient satisfaction with treatment questionnaire for overactive bladder (OAB-PSTQ). Qual Life Res 2005; 14: 2144.
16. The National Collaborating Centre for Chronic Conditions at the Royal College of Physicians. Multiple Sclerosis. 2004. http://www.rcplondon.ac.uk/ pubs/books/ms.
17. Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: A double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2011; 184: 2416-22.
18. Schurch B, Denys P, Kozma CM, et al. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 2007; 52: 850-58.
19. Coyne KS, Elinoff V, Gordon DA, et al. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin Pract 2008; 62: 925-31.
20. Van Kerrebroeck PE, Kelleher CJ, Coyne KS, et al. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health Qual Life Outcomes 2009; 7: 13.
21. Brubaker L, Shull B,. EGGS for patient-centered outcomes. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16: 171-3.
22. Wiklund I,. Assessment of patient-reported outcomes in clinical trials: The example of health-related quality of life. Fundam Clin Pharmacol 2004; 18: 351-63.
23. Carlberg A,. Patient satisfaction and design of treatment. Results: from a study of two different ways of treating hypertension. Scand J Prim Health Care 1993; 11: 105-10.
24. Cleary PD, McNeil BJ,. Patient satisfaction as an indicator of quality care. Inquiry 1988; 25: 25-36.
25. Ware JE, Jr., Davies-Avery A, Stewart AL,. The measurement and meaning of patient satisfaction. Health Med Care Serv Rev 1978; 1: 3-15.